
Sonnet BioTherapeutics Holdings, Inc. Common Stock
SONN
SONN: Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
moreShow SONN Financials
Recent trades of SONN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by SONN's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Followers on SONN's company Twitter account
Number of mentions of SONN in WallStreetBets Daily Discussion
Recent insights relating to SONN
Recent picks made for SONN stock on CNBC
ETFs with the largest estimated holdings in SONN
Flights by private jets registered to SONN